This hypothesis gains support from recent discoveries in cancer research, wherein intra-tumoral injection of cytokines or TLR9 agonists has demonstrated substantially greater effects on tumor size and tumor-specific immune responses compared to the same therapies administered s.c. or i.v.48,49. The gene discussed is TLR9; the disease is cancer.